Sormani MP, Häring DA, Kropshofe H, et al. Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing-remitting multiple sclerosis. ECTRIMS 2017, #277.
Adviespanel FDA positief over donanemab
jun 2024 | Dementie
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen
aug 2021 | Hoofdpijn